SG11201507934PA - Peptide compound - Google Patents
Peptide compoundInfo
- Publication number
- SG11201507934PA SG11201507934PA SG11201507934PA SG11201507934PA SG11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA SG 11201507934P A SG11201507934P A SG 11201507934PA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide compound
- peptide
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013111893 | 2013-05-28 | ||
PCT/JP2014/002772 WO2014192284A1 (en) | 2013-05-28 | 2014-05-27 | Peptide compound |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201507934PA true SG11201507934PA (en) | 2015-10-29 |
Family
ID=50942304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507934PA SG11201507934PA (en) | 2013-05-28 | 2014-05-27 | Peptide compound |
Country Status (36)
Country | Link |
---|---|
US (2) | US10087229B2 (en) |
EP (1) | EP3004155B1 (en) |
JP (2) | JP6429799B2 (en) |
KR (1) | KR102229051B1 (en) |
CN (1) | CN105209485B (en) |
AP (1) | AP2015008781A0 (en) |
AR (1) | AR096440A1 (en) |
AU (1) | AU2014272500B2 (en) |
CA (1) | CA2908581C (en) |
CL (1) | CL2015003031A1 (en) |
CY (1) | CY1124790T1 (en) |
DK (1) | DK3004155T3 (en) |
DO (1) | DOP2015000261A (en) |
EA (2) | EA202090593A3 (en) |
EC (1) | ECSP15044389A (en) |
ES (1) | ES2900744T3 (en) |
GE (1) | GEP201706762B (en) |
HK (1) | HK1216757A1 (en) |
HR (1) | HRP20212014T1 (en) |
HU (1) | HUE057361T2 (en) |
IL (1) | IL242005B (en) |
LT (1) | LT3004155T (en) |
MA (1) | MA38472B1 (en) |
MX (2) | MX2015015464A (en) |
MY (1) | MY172744A (en) |
PE (1) | PE20151770A1 (en) |
PH (1) | PH12015502391B1 (en) |
PL (1) | PL3004155T3 (en) |
PT (1) | PT3004155T (en) |
SG (1) | SG11201507934PA (en) |
SI (1) | SI3004155T1 (en) |
TN (1) | TN2015000451A1 (en) |
TW (1) | TWI638831B (en) |
UA (1) | UA118558C2 (en) |
UY (1) | UY35589A (en) |
WO (1) | WO2014192284A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10087229B2 (en) | 2013-05-28 | 2018-10-02 | Takeda Pharmaceutical Company Limited | Peptide compound |
JOP20200119A1 (en) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | Gip and glp-1 co-agonist compounds |
CN104846061A (en) * | 2015-05-07 | 2015-08-19 | 中国药科大学 | Method for determining receptor affinity of GLP-1 receptor agonist |
CN105388239B (en) * | 2015-12-18 | 2018-01-05 | 兆科药业(合肥)有限公司 | A kind of monitoring method of Solid-phase synthesis peptides |
JP6995042B2 (en) * | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | Peptide compound |
US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JOP20180028A1 (en) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | Peptide compound |
WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
EP3743092A4 (en) | 2018-01-23 | 2021-10-20 | Gila Therapeutics, Inc. | Peptide yy pharmaceutical formulations, compositions, and methods |
JP6818940B2 (en) * | 2018-05-04 | 2021-01-27 | ノヴォ ノルディスク アー/エス | GIP derivatives and their use |
CN110818771B (en) * | 2018-08-14 | 2023-01-17 | 陈铭 | Carbonyl sulfide mediated polypeptide synthesis using amino acid ionic liquids |
WO2020067575A1 (en) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
WO2020067557A2 (en) * | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
MX2022002115A (en) * | 2019-08-19 | 2022-03-17 | Lilly Co Eli | Methods of making incretin analogs. |
KR20210040818A (en) | 2019-10-04 | 2021-04-14 | 한미약품 주식회사 | Composition of Glucagon and Dual GLP-1/GIP receptor agonist, and therapeutic use thereof |
CN110684082B (en) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | GIP and GLP-1 dual-agonist polypeptide compound, pharmaceutically acceptable salt and application |
TW202202516A (en) * | 2020-03-25 | 2022-01-16 | 日商武田藥品工業股份有限公司 | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
TW202214679A (en) | 2020-07-22 | 2022-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1 and gip receptor co-agonists |
BR112023000270A2 (en) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, PEPTIDE |
WO2022253202A1 (en) | 2021-06-01 | 2022-12-08 | 南京知和医药科技有限公司 | Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof |
TW202330584A (en) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Prodrugs and uses thereof |
WO2024012472A1 (en) * | 2022-07-13 | 2024-01-18 | 杭州中美华东制药有限公司 | Glp-1/gip dual agonist, and preparation method therefor and use thereof |
WO2024059674A1 (en) | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Gip and glp-1 dual agonist compounds |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
JP2001504105A (en) | 1996-11-12 | 2001-03-27 | ノボ ノルディスク アクティーゼルスカブ | Use of GLP-1 peptide |
WO1999047161A1 (en) | 1998-03-19 | 1999-09-23 | Bionebraska, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
EP1932535A3 (en) | 1998-07-31 | 2008-10-29 | Novo Nordisk A/S | Stimulation of beta cell profileration |
CZ303120B6 (en) | 1998-12-07 | 2012-04-11 | Societe De Conseils De Recherches Et Dapplications Scientifiques S. A. | Compound and pharmaceutical composition |
AU5675701A (en) | 2000-05-16 | 2001-11-26 | Sanwa Kagaku Kenkyusho Co | Agents for preventing or ameliorating insulin resistance and/or obesity |
ES2327328T3 (en) | 2002-07-04 | 2009-10-28 | Zealand Pharma A/S | GLP-1 AND PROCEDURES FOR THE TREATMENT OF DIABETES. |
ES2393335T3 (en) | 2003-12-16 | 2012-12-20 | Ipsen Pharma | GLP-1 analogues |
WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
MX2007009760A (en) | 2005-02-11 | 2007-11-07 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties. |
WO2006136374A2 (en) | 2005-06-20 | 2006-12-28 | Develogen Aktiengesellschaft | Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells |
US20080015265A1 (en) | 2006-07-11 | 2008-01-17 | Byron Rubin | Methods of treating obesity using satiety factors |
CA2660835A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable propperties |
PE20080840A1 (en) | 2006-09-13 | 2008-08-27 | Smithkline Beecham Corp | METHODS FOR ADMINISTERING LONG-LIVED HYPOGLYCEMIANT AGENTS |
EP1972349A1 (en) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
WO2009067268A1 (en) | 2007-11-23 | 2009-05-28 | Michael Rothkopf | Methods of enhancing diabetes resolution |
EA020326B9 (en) | 2008-06-17 | 2015-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
CA2733006A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal |
EP2373681B1 (en) | 2008-12-10 | 2017-01-18 | Glaxosmithkline LLC | Pharmaceutical compositions of albiglutide |
MX2011013625A (en) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Gip receptor-active glucagon compounds. |
JP5767582B2 (en) | 2009-07-02 | 2015-08-19 | 武田薬品工業株式会社 | Peptides and their uses |
RU2012136450A (en) * | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY |
AR080592A1 (en) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS |
BR112013015861A2 (en) | 2010-12-22 | 2018-06-05 | Marcadia Biotech Inc | methods for reducing weight gain or inducing weight loss, and for treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels. |
EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
US8575090B2 (en) | 2011-06-10 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
KR102002783B1 (en) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
JP6126097B2 (en) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー/エス | GLP-1 derivative |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
JP6228187B2 (en) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | GIP-GLP-1 dual agonist compounds and methods |
JP6250034B2 (en) | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー/エス | Double acylated GLP-1 derivative |
US20150182461A1 (en) | 2012-06-19 | 2015-07-02 | Massachussets Institute Of Technology | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices |
MX2014015558A (en) | 2012-06-21 | 2015-03-05 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity. |
BR112014031671A2 (en) | 2012-06-21 | 2018-08-07 | Hoffmann La Roche | glucagon analogs exhibiting gip receptor activity |
CN104968674A (en) | 2012-12-19 | 2015-10-07 | 诺和诺德股份有限公司 | Novel glp-1 receptor agonists with cholesterol efflux activity |
LT2934568T (en) | 2012-12-21 | 2018-02-12 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
EP3238734A1 (en) | 2013-03-14 | 2017-11-01 | Medimmune Limited | Pegylated glucagon and glp-1 co-agonists for the treatment of obesity |
US10087229B2 (en) | 2013-05-28 | 2018-10-02 | Takeda Pharmaceutical Company Limited | Peptide compound |
MX369770B (en) | 2013-11-06 | 2019-11-21 | Zealand Pharma As | Glucagon-glp-1-gip triple agonist compounds. |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
JP2018012644A (en) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | Peptide compound |
-
2014
- 2014-05-27 US US14/780,579 patent/US10087229B2/en active Active
- 2014-05-27 PT PT147299762T patent/PT3004155T/en unknown
- 2014-05-27 HU HUE14729976A patent/HUE057361T2/en unknown
- 2014-05-27 DK DK14729976.2T patent/DK3004155T3/en active
- 2014-05-27 MX MX2015015464A patent/MX2015015464A/en active IP Right Grant
- 2014-05-27 TN TN2015000451A patent/TN2015000451A1/en unknown
- 2014-05-27 US US14/287,514 patent/US9200051B2/en active Active
- 2014-05-27 KR KR1020157032121A patent/KR102229051B1/en active IP Right Grant
- 2014-05-27 ES ES14729976T patent/ES2900744T3/en active Active
- 2014-05-27 HR HRP20212014TT patent/HRP20212014T1/en unknown
- 2014-05-27 UA UAA201510946A patent/UA118558C2/en unknown
- 2014-05-27 CN CN201480026613.0A patent/CN105209485B/en active Active
- 2014-05-27 LT LTEPPCT/JP2014/002772T patent/LT3004155T/en unknown
- 2014-05-27 MA MA38472A patent/MA38472B1/en unknown
- 2014-05-27 EA EA202090593A patent/EA202090593A3/en unknown
- 2014-05-27 AU AU2014272500A patent/AU2014272500B2/en active Active
- 2014-05-27 SG SG11201507934PA patent/SG11201507934PA/en unknown
- 2014-05-27 GE GEAP201413984A patent/GEP201706762B/en unknown
- 2014-05-27 AR ARP140102090A patent/AR096440A1/en unknown
- 2014-05-27 TW TW103118374A patent/TWI638831B/en active
- 2014-05-27 MY MYPI2015703438A patent/MY172744A/en unknown
- 2014-05-27 CA CA2908581A patent/CA2908581C/en active Active
- 2014-05-27 AP AP2015008781A patent/AP2015008781A0/en unknown
- 2014-05-27 PE PE2015002124A patent/PE20151770A1/en unknown
- 2014-05-27 JP JP2015555470A patent/JP6429799B2/en active Active
- 2014-05-27 SI SI201431933T patent/SI3004155T1/en unknown
- 2014-05-27 PL PL14729976T patent/PL3004155T3/en unknown
- 2014-05-27 EP EP14729976.2A patent/EP3004155B1/en active Active
- 2014-05-27 UY UY0001035589A patent/UY35589A/en not_active Application Discontinuation
- 2014-05-27 EA EA201591891A patent/EA035813B1/en unknown
- 2014-05-27 WO PCT/JP2014/002772 patent/WO2014192284A1/en active Application Filing
-
2015
- 2015-10-11 IL IL242005A patent/IL242005B/en active IP Right Grant
- 2015-10-13 CL CL2015003031A patent/CL2015003031A1/en unknown
- 2015-10-14 PH PH12015502391A patent/PH12015502391B1/en unknown
- 2015-10-15 DO DO2015000261A patent/DOP2015000261A/en unknown
- 2015-10-21 EC ECIEPI201544389A patent/ECSP15044389A/en unknown
- 2015-11-06 MX MX2019010531A patent/MX2019010531A/en unknown
-
2016
- 2016-04-28 HK HK16104856.7A patent/HK1216757A1/en unknown
-
2018
- 2018-06-12 JP JP2018111494A patent/JP6570705B2/en active Active
-
2021
- 2021-12-15 CY CY20211101100T patent/CY1124790T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216757A1 (en) | Peptide compound | |
EP2960234A4 (en) | Trk-INHIBITING COMPOUND | |
GB201302368D0 (en) | Compound | |
HRP20180452T1 (en) | Peptides | |
EP2982674A4 (en) | Pyridinylpyrazoloquinoline compound | |
PL3061771T3 (en) | Novel four-ctl epitope-joined peptide | |
HK1211596A1 (en) | Peptide | |
EP2947066A4 (en) | Phenoxyalkylamine compound | |
HK1211595A1 (en) | Peptide | |
HK1198769A1 (en) | Novel peptide | |
GB201315130D0 (en) | Peptides | |
GB201307331D0 (en) | Compound | |
GB201319776D0 (en) | Compound | |
GB201316660D0 (en) | Peptides | |
GB201315772D0 (en) | Compound | |
GB201300381D0 (en) | Peptides | |
GB201305634D0 (en) | Compound | |
GB201304250D0 (en) | Compound | |
GB201301585D0 (en) | Compound |